Biotie Therapies

Biotie Therapies was a biotechnology company focused on the development of innovative drugs for neurodegenerative and psychiatric disorders. The company was founded in 1998 and was headquartered in Turku, Finland.

History

Biotie Therapies was established in 1998 and quickly became a prominent player in the field of biotechnology. The company specialized in the development of treatments for conditions such as Parkinson's disease, Alzheimer's disease, and alcohol dependence. Over the years, Biotie Therapies entered into several strategic partnerships and collaborations with other pharmaceutical companies to advance its research and development efforts.

In 2016, Biotie Therapies was acquired by Acorda Therapeutics, a U.S.-based biotechnology company, for approximately $363 million. This acquisition allowed Acorda Therapeutics to expand its portfolio of treatments for neurological disorders.

Research and Development

Biotie Therapies focused on the development of drugs targeting the central nervous system. Some of the key areas of research included:

• Parkinson's disease: The company developed several drug candidates aimed at alleviating the symptoms and slowing the progression of Parkinson's disease.
• Alzheimer's disease: Biotie Therapies worked on innovative treatments to address the cognitive decline associated with Alzheimer's disease.
• Alcohol dependence: The company developed treatments to help individuals reduce their alcohol consumption and manage dependence.

Key Products

Biotie Therapies had a pipeline of drug candidates at various stages of development. Some of the notable products included:

• Tozadenant: A drug candidate for the treatment of Parkinson's disease, which aimed to improve motor function and reduce "off" time in patients.
• SYN120: An investigational drug for the treatment of cognitive impairment in Parkinson's disease and Alzheimer's disease.
• Selincro (nalmefene): A medication approved in Europe for the reduction of alcohol consumption in patients with alcohol dependence.

Acquisition by Acorda Therapeutics

In January 2016, Acorda Therapeutics announced its intention to acquire Biotie Therapies. The acquisition was completed in April 2016, and Biotie Therapies became a wholly-owned subsidiary of Acorda Therapeutics. This acquisition provided Acorda with access to Biotie's promising pipeline of drug candidates and expanded its capabilities in the treatment of neurological disorders.

See Also

• Biotechnology
• Pharmaceutical industry
• Neurodegenerative disease
• Psychiatric disorder
• Acorda Therapeutics